Steroid-induced CSC may only occur in vulnerable patients

Article

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science.

For this prospective, pilot study, researchers from the Seoul National University College of Medicine and Bundang Hospital measured choroidal thickness in 35 eyes in 18 patients treated with high-dose systemic corticosteroid pulse therapy (>500 mg/d) at baseline, 1 day, 1 week and 1 month after corticosteroids were administered. Blood pressures were measured four times daily for the first 5 days of treatment as well. High-dose corticosteroid therapy concentrations delivered were 19.5 mg/kg, for a mean of 5.2 days.

At baseline, the mean subfoveal choroidal thickness was 259.8 μm (range: 86.4 to 394.7 μm). No significant changes in choroidal thickness were seen at day 1, week 1, or month 1 after treatment (P = 0.117). In only one patient who presented at baseline with pigment epithelial detachment, bilateral focal subretinal fluid was seen and showed central serous chorioretinopathy, with a 13.1% increase in subfoveal choroidal thickness.

To view an abstract of this study, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.